Literature DB >> 19801574

Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

Ingar Holme1, Are H Aastveit, Niklas Hammar, Ingmar Jungner, Göran Walldius.   

Abstract

AIMS: Few studies have analysed the influence of lipoprotein components (LC) on the development of congestive heart failure (HF) in large healthy populations. We examined LC together with glucose, haptoglobin (Hp), and uric acid (UA) as risk factors for HF in the Apolipoprotein MOrtality RISk (AMORIS) study. We also explored the possible interaction between these factors and the apolipoprotein B to apolipoprotein A-1 ratio (apoB/apoA-1) in HF. METHODS AND
RESULTS: This was a prospective study of HF conducted over 11.8 years through links with the Swedish hospital discharge and mortality registers. Lipoprotein components and other risk factors were measured in 84 740 men and women during health check-ups. All LC were strongly associated with HF per gender adjusted for risk factors. Relationships were stronger for men than for women. Among LC the apoB/apoA-1 ratio was the strongest risk factor for HF in men and triglycerides (TG) in women, but differences in strength were not large. The Hp and UA added predictive information to that of the apoB/apoA-1 ratio, but glucose did not. There was no detectable interaction (synergistic effects) on relative risk between apoB/apoA-1 and these three additional factors.
CONCLUSION: Over and above adjustment factors, the apoB/apoA-1 ratio and TG were the most predictive of the LC, but all LC were highly significantly related to the development of HF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801574     DOI: 10.1093/eurjhf/hfp129

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

1.  Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry.

Authors:  Sean A Agger; Luke C Marney; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2010-10-05       Impact factor: 8.327

2.  Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm.

Authors:  Mary F Lopez; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Oksana Gvozdyak; Sherry Chou; Eng Lo; Ferdinand Buonanno; MingMing Ning
Journal:  Proteomics Clin Appl       Date:  2012-04       Impact factor: 3.494

3.  Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish Heart Health Extended Cohort Study.

Authors:  Stephen P Juraschek; Hugh Tunstall-Pedoe; Mark Woodward
Journal:  Atherosclerosis       Date:  2014-01-30       Impact factor: 5.162

4.  Cholesterol and triglyceride levels in midlife and risk of heart failure in women, a longitudinal study: the prospective population study of women in Gothenburg.

Authors:  Anna-Karin Halldin; Lauren Lissner; Bodil Lernfelt; Cecilia Björkelund
Journal:  BMJ Open       Date:  2020-06-04       Impact factor: 2.692

5.  apoA2 correlates to gestational age with decreased apolipoproteins A2, C1, C3 and E in gestational diabetes.

Authors:  Manjunath Ramanjaneya; Alexandra E Butler; Mohammed Bashir; Ilham Bettahi; Abu Saleh Md Moin; Lina Ahmed; Mohamed A Elrayess; Steven C Hunt; Stephen L Atkin; Abdul Badi Abou-Samra
Journal:  BMJ Open Diabetes Res Care       Date:  2021-03

6.  Apolipoprotein A1 is associated with pulmonary vascular resistance and adverse clinical outcomes in patients with pulmonary hypertension secondary to heart failure.

Authors:  Wande Yu; Xie Dujiang; Wang Yi; Ding Guanwen; Zhang Mengyu; Pan Chang; Zhang Aikai; Zhang Juan; Zhu Linlin; Zhang Hang
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

7.  Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients.

Authors:  Peter P Toth; Sephy Philip; Michael Hull; Craig Granowitz
Journal:  Vasc Health Risk Manag       Date:  2019-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.